SEC Form 4 filed by Bailey Gregory

$AGE
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $AGE alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $AGE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AGE

DatePrice TargetRatingAnalyst
More analyst ratings

$AGE
Press Releases

Fastest customizable press release news feed in the world

See more
  • AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

    ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights. Recent Highlights  ●Stockholders approved transactions for merger with Serina Therapeutics, Inc. ●Obtained $4.4 million addition to line of credit from Juvenescence Limited ●Preferred Stock converted into Common Stock ●Completed reverse stock split at a ratio of 1 for 35.17    Liquidity and Capital Resources Issuance of Preferred Stock to Eliminate $36 Million of Indebtedness and

    $AGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer

    Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TM drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics, today announced Serina has entered into a License Agreement under which Pfizer Inc. will license, on a non-exclusive basis, Serina's POZ polymer technology. "We are excited about the license to Pfizer for its use of the POZ polymer technology in initial research and development acti

    $AGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • AgeX Therapeutics Reports Third Quarter 2023 Financial Results

    AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023. Third Quarter and Recent Highlights $36 Million of Indebtedness Converted into Preferred Stock Signed Agreement and Plan of Merger and Reorganization to Acquire Serina Therapeutics, Inc. Obtained $4.4 million addition to line of credit from Juvenescence Limited Liquidity and Capital Resources Issuance of Preferred Stock to Eliminate $36 Million of Indebtedness During July 2023, AgeX and Juvenescence Limited entered into an Exchange Agreement pursu

    $AGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AGE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AGE
SEC Filings

See more

$AGE
Financials

Live finance-specific insights

See more
  • AgeX Therapeutics Reports Third Quarter 2023 Financial Results

    AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023. Third Quarter and Recent Highlights $36 Million of Indebtedness Converted into Preferred Stock Signed Agreement and Plan of Merger and Reorganization to Acquire Serina Therapeutics, Inc. Obtained $4.4 million addition to line of credit from Juvenescence Limited Liquidity and Capital Resources Issuance of Preferred Stock to Eliminate $36 Million of Indebtedness During July 2023, AgeX and Juvenescence Limited entered into an Exchange Agreement pursu

    $AGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock

    AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 24, 2023, AgeX issued to Juvenescence Limited 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans. The cancellation of indebtedness in exchange for the Preferred Stock was conducted pursuant to an Exchange Agreement between AgeX and Juvenescenc

    $AGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock

    AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 21, 2023, AgeX and Juvenescence Limited entered into an Exchange Agreement pursuant to which AgeX agreed to issue to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans. The exchange of the indebtedness for shares of Series A Pre

    $AGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AGE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more